XML 97 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Senior convertible notes due 2022
Senior convertible notes due 2023
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Senior convertible notes due 2022
Additional Paid-In Capital
Senior convertible notes due 2023
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Treasury Stock
Balance at beginning of period (shares) at Dec. 31, 2016       84,600,000            
Balance at beginning of period at Dec. 31, 2016 $ 283.8     $ 0.1 $ 905.7     $ (1.0) $ (621.0) $ 0.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock under equity incentive plans (shares)       2,300,000            
Issuance of common stock under equity incentive plans 2.7       2.7          
Issuance of common stock for Employee Stock Purchase Plan (shares)       100,000            
Issuance of common stock for Employee Stock Purchase Plan 7.4       7.4          
Share-based compensation expense 106.7       106.7          
Equity component of convertible note issuance, net of issuance costs   $ 70.6       $ 70.6        
Cumulative effect of adoption of new accounting pronouncement | Accounting Standards Update 2016-09         0.6       (0.6)  
Net income (loss) (50.2)               (50.2)  
Other comprehensive income (loss) (1.6)             (1.6)    
Balance at end of period (shares) at Dec. 31, 2017       87,000,000.0            
Balance at end of period at Dec. 31, 2017 419.4     $ 0.1 1,093.7     (2.6) (671.8) 0.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock under equity incentive plans (shares)       1,800,000            
Issuance of common stock under equity incentive plans 1.9       1.9          
Issuance of common stock for Employee Stock Purchase Plan (shares)       200,000            
Issuance of common stock for Employee Stock Purchase Plan 8.9       8.9          
Share-based compensation expense 101.9       101.9          
Equity component of convertible note issuance, net of issuance costs (218.9)   $ 171.6   (218.9)   $ 171.6      
Issuance of common stock for collaborative research and development fee (shares)       1,800,000            
Issuance of common stock for collaborative research and development fee 217.7       217.7          
Sale of warrants $ 183.8       183.8          
Purchases of treasury stock (shares) (800,000)     (800,000)            
Purchases of treasury stock $ (100.0)                 (100.0)
Net income (loss) (127.1)               (127.1)  
Other comprehensive income (loss) 4.1             4.1    
Balance at end of period (shares) at Dec. 31, 2018       90,000,000.0            
Balance at end of period at Dec. 31, 2018 663.3     $ 0.1 1,560.6     1.5 (798.9) (100.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock under equity incentive plans (shares)       1,400,000            
Issuance of common stock under equity incentive plans 0.3       0.3          
Issuance of common stock for Employee Stock Purchase Plan (shares)       200,000            
Issuance of common stock for Employee Stock Purchase Plan 11.6       11.6          
Share-based compensation expense 102.7       102.7          
Cumulative effect of adoption of new accounting pronouncement | Accounting Standards Update 2016-02 $ 2.1               2.1  
Purchases of treasury stock (shares) 0                  
Realization of tax benefit related to 2023 Note Hedge $ 0.7       0.7          
Net income (loss) 101.1               101.1  
Other comprehensive income (loss) 0.8             0.8    
Balance at end of period (shares) at Dec. 31, 2019       91,600,000            
Balance at end of period at Dec. 31, 2019 $ 882.6     $ 0.1 $ 1,675.9     $ 2.3 $ (695.7) $ (100.0)